کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2999843 | 1180306 | 2010 | 6 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Evidence for Cytogenetic and Fluorescence In Situ Hybridization Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
IgHNot reachedmSMARTPCLIScT - ScT درImmunoglobulin heavy chain - زنجیره سنگین ایمونوگلوبولینCytogenetics - سیتوژنتیک plasma cell labeling index - شاخص نشانه گذاری سلول های پلاسماconfidence interval - فاصله اطمینانfluorescence in situ hybridization - فلورسانس در هیبریداسیون در محلFish - ماهیMultiple myeloma - مولتیپل میلوماhazard ratio - نسبت خطرStem cell transplantation - پیوند سلول بنیادی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Overall survival (OS) has improved with increasing use of novel agents in multiple myeloma (MM). However, the disease course remains highly variable, and the heterogeneity largely reflects different genetic abnormalities. We studied the impact of the Mayo risk-stratification model of MM on patient outcome in the era of novel therapies, evaluating each individual component of the model-fluorescence in situ hybridization (FISH), conventional cytogenetics (CG), and the plasma cell labeling index-that segregates patients into high- and standard-risk categories. This report consists of 290 patients with newly diagnosed MM, predominantly treated with novel agents, who were risk-stratified at diagnosis and were followed up for OS. Of these patients, 81% had received primarily thalidomide (n=50), lenalidomide (n=199), or bortezomib (n=79) as frontline or salvage therapies. Our retrospective analysis validates the currently proposed Mayo risk-stratification model (median OS, 37 months vs not reached for high- and standard-risk patients, respectively; P=.003). Although the FISH or CG test identifies a high-risk cohort with hazard ratios of 2.1 (P=.006) and 2.5 (P=.006), respectively, the plasma cell labeling index cutoff of 3% fails to independently prognosticate patient risk (hazard ratio, 1.4; P=.41). In those stratified as standard-risk by one of the 2 tests (FISH or CG), the other test appears to be of additional prognostic significance. This study validates the high-risk features defined by FISH and CG in the Mayo risk-stratification model for patients with MM predominantly treated with novel therapies based on immunomodulatory agents.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Mayo Clinic Proceedings - Volume 85, Issue 6, June 2010, Pages 532-537
Journal: Mayo Clinic Proceedings - Volume 85, Issue 6, June 2010, Pages 532-537
نویسندگان
Prashant MD, Rafael MD, S. Vincent MD, Shirshendu MBBS, Morie A. MD, A. Keith MD, P. Leif MD, Martha Q. MD, David D. MD, PhD, Rhett P. MD, Francis MD, Robert A. MD, Thomas E. MD, Philip R. MD, Angela MD, Shaji MD,